N/A N=60 Subcutaneous Fat Reduction in the Submental Area
Body Fat Disorder
Primary: Safety of CoolScupting in the Submental Area — 4 incidence of device- and/or procedure AE
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
N/A N=93 Exercise Regulation of Human Adipose Tissue
Healthy · Obese · Diabetes Mellitus, Type 2
Primary: Changes in Human Adipose Tissue Characteristics Following Exercise Training — 25.45; 34.12; 38.06; 27.05 body fat %
N/A N=60 Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound
Treatment of Adipose Tissue in the Thighs
Primary: Clinical Improvement in Thigh Circumference — -1.22; -0.59 centimeter
N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
N/A N=60 Non-invasive Cooling of Subcutaneous Fat
Fat Disorder
Primary: Change in Fat Layer Thickness of the Treated Flank — -18.7; -22.6; -17.8; -17.5 percent fat layer change
Phase 4 N=16 Submental Study (Sequential Treatment Approach)
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Phase 2 N=48 Adipose Tissue Extract and Platelet-rich Plasma Use for Wound Healing
Wound Healing Disturbance of
Primary: Wound Re-epithelization — 12.34; 10.27; 11.33 days
N/A N=40 Diagnostic Ultrasound for Measuring Fat of the Body
Subcutaneous Fat
Primary: Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body — .56; .60; .83; 1.65 average fat measurement (cm)
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
Phase 3 N=793 Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Central Abdominal Bulging
Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397
Phase 4 N=38 Liraglutide Effects on Epicardial Fat Inflammatory Genes
Type2 Diabetes · Coronary Artery Disease
Primary: EAT Inflammation — 0.70; 1.4; 0.39; 0.25 ct (cycle threshold)
N/A N=20 CoolSculpting in the Abdomen Using Applicator With and Without CCI
Body Fat Disorder
Primary: Percentage of Accurately Identified Pre-treatment Photos — 33; 23; 50; 23 photos
N/A N=19 Fat Layer Reduction in the Lateral Thighs Using CoolSculpting
Body Fat Disorder
Primary: Safety of the Zeltiq CoolSculpting System in the Outer Thighs — 8; 0 events
N/A N=175 Non-Invasive Cooling of Fat Cells
Reduction of Unwanted Fat
Primary: Percentage of Participants With Visible Improvement in Treated Area — 65.2; 82.8 percentage of participants
N/A N=60 Non-Invasive Reduction of Abdominal Fat
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Phase 4 N=4 Subcutaneous vs. Intramuscular Testosterone
Testosterone Deficiency · Hypogonadism, Male
Primary: Change in Levels of Serum Total Testosterone Concentration — NA; 1043.6; NA; 785.7 ng/dl
N/A N=14 Fat Reduction in the Submandibular/Submental Area
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos
N/A N=39 Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
N/A N=12 Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat
Body Fat
Primary: Number of Participants Who's Abdominal Tissue Showed Necrosis or Inflammatory Immune Cell Response — 10; 0 Participants
Phase 2 N=20 Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts
Breast Reconstruction · Contour Irregularities · Volume Insufficiency
Primary: Volume Maintenance — 51.6; 78.9 percentage of graft volume persistency — p=0.310
N/A N=20 Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
Obesity, Visceral · Obesity; Endocrine
Primary: Visceral Fat Loss (cm3) — -628 cm3
Phase 3 N=59 Rosuvastatin in Visceral Adiposity
Abdominal Obesity
Primary: Change in Visceral Adipose Tissue Area Measured by Computed Tomography. — -1.5; 2.8 cm2
N/A N=19 Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction
Body Fat Disorder
Primary: Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel…
Phase 2 N=25 A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
Subcutaneous Fat
Primary: Number of Treatment Emergent Adverse Events — 103; 57; 69; 61 number of events
N/A N=69 Brown Adipose Tissue Activity in Pre- and Postmenopausal Women
Menopause · Obesity
Primary: Brown Adipose Tissue Volume — 53.1; 20.6 mL
N/A N=32 Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
Metabolic Diseases
Primary: Collection of Imaging of BAT by Magnetic Resonance Imaging — 78.69; 82.58; 82.45 Percentage
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR
N/A N=48 Acute Subcutaneous Defibrillation
Ventricular Arrhythmias
Primary: Subjects Will Demonstrate a Successful Defibrillation Outcome if They Have 2 Successful Defibrillation Shocks With the Research System. — 85.7 percentage of success